Navigation Links
Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Date:2/14/2011

DURHAM, N.C., Feb. 14, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.

Proceeds from this financing will be used to support the development of Chimerix's two clinical-stage candidates, CMX001 and CMX157.  CMX001 is in clinical development as a broad spectrum antiviral for the treatment of life-threatening viral infections in immunocompromised patients, and has a potential dual use as a medical countermeasure in the event of a smallpox release.  Chimerix is evaluating CMX001 in an ongoing Phase 2 clinical study of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients, and in an Open-Label Study under an expanded access protocol for the treatment of critically-ill patients with any of 12 different double-stranded DNA viral infections.  A Phase 2 clinical trial of CMX001 in pediatric and adult hematopoietic stem cell transplant patients with adenovirus related diseases is currently being initiated. Chimerix recently completed a Phase 1 clinical trial of CMX157, a potent nucleoside analogue in development for the treatment of HIV infections, including those caused by multi-drug resistant viruses.

"Development of our two clinical-stage antiviral therapeutics is rapidly accelerating.  We are truly pleased to receive this strong support from leading life science investors for Chimerix's ground-breaking programs," said Kenneth I. Moch, President and CEO of Chimerix. "We are extremely enthusiastic about the very real prospects for Chimerix's drugs to dramatically improve the treatment of deadly viral infections."  

In conjunction with this financing, James Niedel, M.D., Ph.D.,Managing Director of New Leaf Venture Partners, and Arthur M. Pappas, Managing Partner of Pappas Ventures, will join Chimerix's Board of Directors.  Graham Crooke, M.D., of Helix Ventures will retire from the Chimerix Board.  The total number of Chimerix Board members is eight.

"It's rare to find drugs in development with excellent safety and efficacy to treat life-threatening infections in children and adults.  It's equally rare to find a management team with the experience, accomplishments and expertise necessary to progress those drugs through FDA approval and into clinical practice.  In Chimerix, we found both.  I am pleased to join a fine group of investors and board directors in support of those efforts," said Dr. Niedel.

"We are pleased to support Chimerix's important product development programs," said Mr. Pappas.  "We look forward in particular to meaningful clinical results from CMX001 during 2011 and 2012."

"Chimerix has established a cutting-edge portfolio of novel antiviral medicines with the potential to transform the treatment of certain viruses and address critically-ill patients for whom there would otherwise be little or no hope.  We are delighted that such an outstanding group of new investors has joined us in supporting Chimerix in the development of these compounds," said Seth Rudnick, M.D, Venture Partner, Canaan Partners, on behalf of the Chimerix Board.

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  

The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases.  Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.  

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses.  The Open-Label Study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs.  CMX001 has been well tolerated in all studies.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release.  Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies.  Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses.  A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.  

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.  For additional information on Chimerix, please visit http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
2. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
3. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
4. Chimerix to Present at Upcoming Investor Conferences
5. Chimerix Initiates Phase 1 Study of CMX157
6. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
7. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
8. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
9. Chimerix Joins International Network of Organizations to Cure Malaria
10. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
11. Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimers Disease Drug Treatment Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , ... May 25, 2016 , ... ... a Thai delegation at BIO 2016 in San Francisco. Located at booth number ... be available to answer questions and discuss the Thai biotechnology and life sciences ...
(Date:5/25/2016)... ... May 25, 2016 , ... The ... by the Office of the National Coordinator for Health IT (ONC) outlining a ... clinically relevant data were available when and where it was needed. The organization ...
(Date:5/25/2016)... ... 2016 , ... Lady had been battling arthritis since the age of two ... knee. Lady’s owner Hannah sought the help of Dr Jeff Christiansen of Superior ... cruciate ligament and help with the pain of Lady’s arthritis. Dr Christiansen suggested that ...
(Date:5/24/2016)...   MedyMatch Technology Ltd ., the data analytics healthcare ... support tools in the emergency room, announced today that it ... Technology Industries (IATI) BioMed Conference. The Conference ... National Life Sciences and Technology Week, and is being held ... Tel Aviv, Israel . Gene Saragnese ...
Breaking Biology Technology:
(Date:3/15/2016)... March 15, 2016 --> ... by Transparency Market Research "Digital Door Lock Systems Market - ... - 2023," the global digital door lock systems market in ... 2014 and is forecast to grow at a CAGR of ... small and medium enterprises (MSMEs) across the world and high ...
(Date:3/14/2016)... , March 14, 2016 NXTD ... growing mobile commerce market, announces the airing of a new ... starting the week of March 21 st .  The commercials ... including its popular Squawk on the Street show. --> ... on the growing mobile commerce market, announces the airing of ...
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
Breaking Biology News(10 mins):